Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T-cell Lymphoma
2017-000433-30Phase 2Unknown
- Sponsor
- University College London
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cutaneous T-cell lymphoma (CTCL), sponsored by University College London. Primary endpoint: Tumour response rate at infusion 9. Status: unknown.
02
Drugs
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on 2017-000433-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000433-30.